NASDAQ: AGRX Agile Therapeutics Anticipates Increased Growth In Q3 of 2022 By: TheNewswire.com October 21, 2022 at 11:00 AM EDT Contact DetailsMatt Riley - Head of Investor Relations & Corporate Communicationsmriley@agiletherapeutics.comCompany Websitehttps://agiletherapeutics.com/
Contact DetailsMatt Riley - Head of Investor Relations & Corporate Communicationsmriley@agiletherapeutics.comCompany Websitehttps://agiletherapeutics.com/